智通财经网·2025-10-31 02:19Core Viewpoint - Fosun Pharma's stock has seen an increase of nearly 4%, with a current price of HKD 23.16, following the release of its financial results for the nine months ending September 30, 2025, which showed a mixed performance in revenue and profit [1] Financial Performance - The company reported a revenue of CNY 29.393 billion, a decrease of 4.91% year-on-year [1] - Net profit attributable to shareholders was CNY 2.523 billion, reflecting a year-on-year increase of 25.5% [1] - Basic earnings per share stood at CNY 0.95 [1] Key Drivers of Performance - The increase in net profit is primarily attributed to gains from the sale of remaining equity in United Family Healthcare and other non-core assets [1] - The company has been actively pursuing the launch of innovative products, with recent approvals for new indications and products in both domestic and international markets [1] Product Development and Market Expansion - In Q3 2025, Fosun Pharma continued to advance its innovative drug launches, including the approval of a new indication for the small molecule CDK4/6 inhibitor, Ruzhoning, in September [1] - The HLX14 injection has received approval for sale in the US and EU, while the FKC889 injection has been submitted for domestic approval and accepted by the National Medical Products Administration [1] - Analysts believe that the ongoing launch of innovative drug products will drive revenue recovery for the company [1]